N/A N=31 Characterising the Stable and Dynamic Left Atrial Substrate in Atrial Fibrillation
Atrial Fibrillation
Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=110 A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation
Atrial Fibrillation
Primary: Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse…
Phase 4 N=24 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit
Atrial Fibrillation
Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants
Phase 4 N=59 Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial Fibrillation
Primary: Number of Days on Anticoagulation — 24.9 days
N/A N=157 AVAI: Atrial Ventricular Arrythmia Incidence
Ventricular Tachycardia · Atrial Fibrillation
Primary: Slow Ventricular Tachycardia Episodes Devices Detected (Between 120-150 Bpm and > 30sec) Atrial Fibrillation (AF) Episodes Devices Detected (> 30 Sec) — 3778; 112; 68…
N/A N=3,160 Exclusion of Intra-atrial Thrombus Before Catheter Ablation
Atrial Fibrillation · Thrombi
Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants
N/A N=262 iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology
Atrial Fibrillation · Atrial Flutter
Primary: Rate of Recurrence of Atrial Arrhythmias — 0.132; 0.091 episodes per person-month of follow-up — p=0.05
Phase 4 N=67 Heart Rate Regularization in Patients With Permanent Atrial Fibrillation Post Marketing Study
Permanent Atrial Fibrillation
Primary: Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE) — 32; 32; 15; 15 participants — p=<0.0001
N/A N=107 The Dynamics of Human Atrial Fibrillation
Atrial Fibrillation · Atrial Tachyarrhythmia
Primary: Survival Free of Atrial Fibrillation — 28; 31 participants
N/A N=5 Multipolar Mapping and Atrial Arrhythmias
Atrial Fibrillation or Atrial Flutter
Primary: Atrial Fibrillation Dominant Frequency
N/A N=498 Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmias
Cardiac Arrhythmia · Atrial Fibrillation
Primary: Compare the Diagnostic Performance of Physician Rhythm Interpretation of 1-lead ECG Generated by SkyLabs CART-I Ring and Apple Watch Versus 12-lead ECG (Gold-standard)…
N/A N=411 Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation
Heart Failure · Atrial Fibrillation
Primary: Composite of All-cause Mortality and Heart Failure Events — 50; 64 Participants
N/A N=35 Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial
Atrial Fibrillation · Arrhythmias, Cardiac
Primary: Recurrence Rate of Atrial Arrhythmias — 8; 14; 7; 1 participants — p=0.047
Phase 3 N=458 Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)
Atrial Fibrillation
Primary: Postoperative Atrial Fibrillation — 27.2; 27.8; 25.9 percentage of patients — p=0.95
N/A N=100 A Study of Prolonged Electrocardiographic Monitoring in Patients With Heart Failure in Sinus Rhythm or Atrial Fibrillation
Heart Failure · Atrial Fibrillation
Primary: Number of Participants With an Identified Dysrhythmia on Baseline ECG Recording — 25; 35 Participants
N/A N=16 AF Septal Pacing (Clinical Investigation Plan)
Paroxysmal Atrial Fibrillation · Persistent Atrial Fibrillation
Primary: Number of Electrodes in a Stable Position — 38 Electrode pairs
Phase 3 N=127 First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)
Atrial Fibrillation
Primary: Number of Participants With Recurrence of Atrial Tachyarrhythmia — 36; 44 Participants — p=0.0016
N/A N=83 Effectiveness of Ripple Mapping in Atrial Tachycardia Ablation
Atrial Tachycardia
Primary: A Composite of the Total Number of Participants With Either Tachycardia Change or Tachycardia Termination With First Ablation Set. — 38; 29 Participants
N/A N=100 The HOLIDAY (HOw ALcohol InDuces Atrial TachYarrhythmias) Study
Atrial Fibrillation · Alcohol
Primary: Number of Participants With Atrial Fibrillation Induction — 22; 24 Participants
N/A N=24 Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study
Persistent Atrial Fibrillation · Longstanding Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants
N/A N=41 Curing Atrial Fibrillation in Heart Failure
Chronic Heart Failure · Atrial Fibrillation
Primary: Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)% — 2.8; 4.5 percentage of blood ejected in one beat
N/A N=55 Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Atrial Fibrillation (AF) Burden Defined as the Mean Amount of Time Spent in AF Over a Pre-specified Period of Time (Excluding Short AF Episodes of ≤30 Seconds) by the…
N/A N=53 Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation
Atrial Fibrillation · Inflammation
Primary: Atrial Fibrillation Burden — 2; 8.5 Percent time spent in atrial fibrillatio
Phase 2 N=134 Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
Atrial Fibrillation
Primary: Atrial Fibrillation Burden (AFB) at Baseline — 12.7; 10.8; 11.6; 11.7 Percentage of total recording time
Phase 2 N=171 Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305
Atrial Fibrillation
Primary: Dose-response Relationship for QTcF Interval of AZD1305 — 461; 486; 490; 482 ms
Phase 2 N=59 Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias
Premature Atrial Contraction
Primary: Change in Premature Atrial Contractions (PACs) — -0.6; -5.6 Episodes/hour
Phase 3 N=523 Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation
Postoperative Atrial Fibrillation
Primary: Total Number of Days in Hospital — 5.1; 5.0 days — p=0.76
Phase 4 N=396 TReatment of Atrial Fibrillation With Dual dEfibrillator in Heart Failure Patients
Heart Failure, Congestive
Primary: Unplanned Hospital Admissions for Cardiac Reasons OR Death of Cardiovascular Causes OR Progression to Chronic Atrial Fibrillation — 43; 44 participants
N/A N=365 ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation
Persistent Atrial Fibrillation · Longstanding Persistent Atrial Fibrillation
Primary: The Number of Participants Free From Atrial Fibrillation (AF), Atrial Flutter or Atrial Tachycardia While Off Class I and Class III Antiarrhythmic Drugs for at Least 4…
Phase 3 N=55 AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation
Atrial Fibrillation
Primary: Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months. — 74 percentage of subjects